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CASE PRESENTATIONS
Patient 1
A 65-year-old black woman came to the emergency room
of Jackson Memorial Hospital complaining of shortness of
breath and leg swelling of 1-month duration. Her physician
had retired and she had not been seen by a doctor in 5 years.
She presented with a history of dyspnea on minimal exertion,
two-pillow orthopnea, and paroxysmal nocturnal dyspnea.
There was no history of chest pain, myocardial infarction, or
diabetes mellitus. She had quit smoking 10 years previously.
She had no family history of coronary artery disease, but a
younger brother had hypertension and renal failure and was
receiving dialysis.
The patient’s height was 5 feet 2 inches and her weight was
150 pounds. Blood pressure was 170/100 mm Hg; pulse, 100
beats/min and regular; and respirations, 28 breaths/min. On
physical examination, she appeared to be in moderate respira-
tory distress. Funduscopic examination showed arteriovenous
nicking. An S3 and S4 gallop were heard on cardiac auscultation.
The point of maximal impulse (PMI) was felt in the sixth
intercostal space. Lung examination revealed bibasilar dullness
to percussion and rales halfway up bilaterally. The abdomen
was soft, with mild tenderness on deep palpation of the right
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upper quadrant and no masses. The liver was three finger-
breadths below the costal margin. The extremities were warm,
with palpable pulses and 2 pitting edema below the knees.
Laboratory studies revealed a serum creatinine of 6.9 mg/dL
and a blood urea nitrogen (BUN) of 107 mg/dL. The serum
sodium was 137 mmol/L; potassium, 5.2 mmol/L; chloride, 98
mmol/L; and bicarbonate, 17 mmol/L. The total cholesterol
was 160 mg/dL; high-density lipoprotein cholesterol (HDL-C),
44 mg/dL; low-density lipoprotein cholesterol (LDL-C), 96
mg/dL; and triglycerides, 160 mg/dL. The findings on an electro-
cardiogram indicated left-ventricular hypertrophy (LVH). A
chest radiograph showed cardiomegaly, bilateral pleural effu-
sions, and pulmonary vascular redistribution. A renal ultra-
sound demonstrated bilaterally small, echogenic kidneys with
no obstruction. An echocardiogram revealed concentric LVH
and an ejection fraction of 35%. The urinalysis showed 3
protein and 2 to 5 red blood cells, 10 to 20 white blood cells,
and 1 to 2 granular casts per high-power field. The 24-hour
urinary protein excretion was 2.5 g. Creatinine clearance was
7 mL/min. The hemoglobin was 8.5 g/dL; hematocrit, 25%;
and glucose, 102 mg/dL.
Treatment was initiated with furosemide, amlodipine, and
metoprolol. After diuresis, the orthopnea and the paroxysmal
nocturnal dyspnea improved, and the blood pressure decreased
to 160/95 mm Hg. The chest radiograph findings also improved.
However, the pedal edema persisted. It was decided that the pa-
tient had chronic renal failure secondary to hypertension and
that placement of an arteriovenous fistula for hemodialysis was
indicated. The patient was discharged after she was instituted
on a sodium- and potassium-restricted diet and was scheduled
to return to the outpatient clinic in 1 week for follow-up and
further control of blood pressure.
Patient 2
A 50-year-old woman was referred to the Franz Volhard
Clinic in Berlin for the evaluation of arterial hypertension [1].
At that time, she was taking no antihypertensive medications.
The condition had been diagnosed when she was 15 years old,
but no treatment had been initiated. At age 31, her blood
pressure increased precipitously during her only pregnancy,
which nevertheless culminated in the otherwise uncomplicated
delivery of a daughter. Subsequently, a variety of medications
only modestly controlled the patient’s blood pressure. Seven
years ago, an extensive evaluation was performed at another
hospital, but control of her blood pressure was not achieved.
Her only complaints were occasional nausea, headache, and
lightheadedness. She denied dyspnea on exertion, chest pain,
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or visual disturbances. There was no history of cerebrovascular
or cardiovascular disease. The rest of her medical history was
unremarkable, with the exception of brachydactyly. A geneti-
cist at another university had seen her when she was 27 years
old, and type E brachydactyly was diagnosed. No connection
between the brachydactyly and hypertension was made at that
time.
The patient was born in Silesia (Poland). Her mother also
had had brachydactyly, as did other members of the family.
Her brother, the sole sibling, did not have brachydactyly. Since
moving to Germany, she had no further contact with any of
her family members. Her daughter’s development apparently
was normal. The patient could give no information regarding
the daughter’s blood pressure, or even whether the blood pres-
sure had ever been measured.
The patient was 157 cm tall and weighed 47 kg. Her blood
pressure was 280/160 mm Hg; pulse, 80 beats/min and regular;
and respirations, 16 breaths/min. The physical examination,
with the exception of short stature and brachydactyly, was
unremarkable. Funduscopic examination disclosed no hemor-
rhages or exudates. The heart was not palpably enlarged. She
had no cardiac murmurs or gallops. The lungs were clear to
auscultation. No bruits were heard over any vessels.
Laboratory examination showed normal blood count, urinal-
ysis, and serum chemistries, including electrolytes. The creati-
nine clearance was 76 mL/min; sodium excretion, 122 mmol/
day; potassium excretion, 38 mmol/day; and calcium excretion,
1.3 mmol/day. Plasma renin activity and plasma aldosterone
(supine posture) were 14 ng/mL/hour and 666 pg/mL, respec-
tively; the urinary aldosterone excretion was 16.7g/day. Bilat-
eral adrenal vein aldosterone sampling revealed no lateraliza-
tion. Plasma and urinary norepinephrine values were normal.
The renal and adrenal ultrasound examinations were normal.
An echocardiogram disclosed moderate concentric LVH with-
out diastolic dysfunction and with a preserved ejection fraction.
A 24-hour ambulatory blood pressure measurement confirmed
severe hypertension; however, the nocturnal blood pressure
decrease was preserved. Her blood pressure was successfully
reduced with hydrochlorothiazide, triamterene, amlodipine,
enalapril, and carvedilol. She did not return to the clinic and
was lost to follow-up.
DISCUSSION
Dr. Leopoldo Raij (Professor of Medicine, Director of
Hypertension, Nephrology-Hypertension Division; Vice
Chair, Vascular Biology Institute; University of Miami
School of Medicine; Chief, Nephrology-Hypertension
Section, Veterans Affairs Medical Center, Miami, Flor-
ida): I have chosen this case from our own hospital to
contrast with a case presented at a Nephrology Forum
2 years ago by Dr. Freidrich Luft [1]. Although both
patients presented with severe hypertension, end-organ
injury differed dramatically in each. We will use these
patients to analyze the factors that I believe affect the
relationships between hypertension and end-organ dam-
age. The prevalence of renal failure, LVH, and stroke,
the major causes of morbidity and mortality in hyperten-
sion, varies between 10% and 40% in different popula-
tions of hypertensives [2]. A recent study reported the
relationship between blood pressure and mortality due
to coronary artery disease (CAD) independently of
smoking and hypercholesterolemia among men world-
wide [3]. In this 25-year follow-up, the investigators
found that the relative increase in mortality from CAD
for a given increase in blood pressure was similar among
the populations of different countries. However, the ac-
tual rates of mortality for CAD were higher in northern
Europe and the United States compared with Japan and
Mediterranean southern Europe. This study documents
striking variations of end-organ disease in humans with
hypertension of similar severity, alterations that might
be conditioned by genetic as well as environmental fac-
tors [3]. My thesis is that end-organ damage results from
end-organ susceptibility, which is conditioned by genetic
factors and often modified by environmental factors.
During my discussion I will particularly focus on abnor-
malities that affect glomerular regulation of flows and
pressures and on abnormalities that might affect in-
flammatory responses elicited in response to injury in-
duced by the hemodynamic stress of hypertension.
The angiotensin II–nitric oxide axis in hypertension
Three major factors participate in the pathogenesis
of hypertension via the angiotensin II-nitric oxide axis:
abnormal vascular tone, alterations in salt and volume
regulation, and remodeling of the vessel wall resulting
in a reduction of the lumen-to-wall ratio [4, 5].
Angiotensin II (Ang II) is a powerful vasoconstrictor
with pleiotropic actions, including stimulation of growth-
promoting responses as well as production of reactive
oxygen species [6]. In the kidney, the vasoconstrictor
effect of Ang II is particularly effective at the level of the
mesangium and the efferent arteriole [4–6]. The effect of
Ang II in the afferent arteriole is diminished by the
vasodilatory effect of nitric oxide (NO) [7] as well as
molecules synthesized via the cytochrome P-450-depen-
dent pathway [8]. Nitric oxide appears to be a more
effective modulator of Ang II-mediated vasoconstriction
in cortical than in medullary nephrons.
Most of the actions of Ang II are systematically antag-
onized by NO [9] (Fig. 1). Nitric oxide is a vasodilator
with anti-growth and anti-thrombogenic activity that
plays important roles in maintaining the homeostasis of
the vascular wall and preventing damage of end organs.
The production of NO is continuous, thereby imparting
a constant vasodilatory effect, which contributes to main-
taining a resting vascular tone [4]. On the other hand,
Ang II production is not as constant, and its physiologic
role is sustaining vascular tone in response to a decrease
in blood volume and/or renal perfusion pressure [10].
Nitric oxide might have a regulatory role in salt excre-
tion by directly decreasing tubular sodium reabsorption
and increasing renal medullary blood flow. Angiotensin
II is predominantly antinatriuretic; it increases tubular
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Fig. 1. Nitric oxide-angiotensin II (Ang II)-endothelin-1 (ET-1)-aldo-
sterone interactions. Abbreviations are: O2 , superoxide anion; MC,
mesangial cells; VSMC, vascular smooth muscle cell; AT1, Ang II type
1 receptor; AT2, Ang II type 2 receptor; ACE, angiotensin-converting
enzyme; , inhibition;, upregulation (from [9], with permission).
sodium reabsorption and modulates the feedback regula-
tion of renin release at the macula densa [4, 11]. Synthesis
of endothelin-1, a powerful vasoconstrictor, is up-regu-
lated by Ang II and down-regulated by NO.
Angiotensin II affects growth-related processes di-
rectly and indirectly by means of synthesis of growth
factors such as transforming growth factor- (TGF-)
and platelet-derived growth factor [12]. But NO down-
regulates TGF- and is an important inhibitor of growth-
related responses in mesangial cells, vascular smooth
muscle cells, and extracellular matrix [13]. Nitric oxide
is a powerful inhibitor of platelet aggregation and of
the expression of adhesion molecules that participate
in vascular inflammatory responses. Also, NO down-
regulates the synthesis of both angiotensin II-converting
enzyme (ACE) as well as the synthesis of angiotensin
type 1 receptors [14]. Furthermore, inhibition of NO
synthesis increases synthesis of Ang II and ACE in the
kidney as well as in the aorta [15]. The interaction be-
tween NO and endothelin-1, however, appears to be
more important under pathologic than physiologic con-
ditions [9, 16].
Angiotensin II’s ability to activate NADH/NADPH
oxidases has received much attention. Angiotensin II
drives the production of superoxide anion by activating
NADH/NADPH oxidases present in vascular smooth
muscle, endothelial and mesangial cells, and aortic ad-
ventitial fibroblasts [17–19]. Superoxide anion (O2 ) acti-
vates mitogen-activated protein (MAP) kinases and
leads to vascular smooth muscle and mesangial cell hy-
pertrophy as well as hyperplasia [19]. Superoxide anion
has very high affinity for NO, and the interaction of
superoxide and NO generates peroxynitrite, which is by
itself a powerful oxidant molecule. Peroxynitrite induces
release of zinc from the zinc-thiolate center of nitric
oxide synthase (NOS), which results in NOS functional
uncoupling due to a shift of this enzyme from its dimeric
form to a monomeric form [20]. Paradoxically, a dysfunc-
tional NOS produces more O2 than NO and initiates a
vicious circle that maintains increased O2 production
and decreased bioactivity of NO [20].
Vascular remodeling is an active process of adaptation
of the vascular beds to the hemodynamic workload im-
posed by hypertension [21, 22]. In vessels, it is character-
ized by changes in the media-to-lumen ratio, and in the
glomerulus by an increase in size and number of mesan-
gial cells and/or the amount of mesangial matrix [12,
13, 22, 23]. In the heart, remodeling produces myocyte
hypertrophy and increased matrix [21, 22]. In many pa-
tients these adaptive changes are often maladaptive,
leading to ischemia to vascular territories, renal failure,
LVH, and heart failure, as well as CAD [24]. The vascu-
lar remodeling that occurs in hypertension and athero-
sclerosis is in part due to the loss of NO bioactivity,
which results in a functional imbalance between Ang II
and NO (Fig. 1) [9, 21].
What have we learned from experimental studies?
Studies in genetic models of hypertension have greatly
contributed to our understanding of the relationship be-
tween blood pressure and renal disease [2, 23, 25, 26].
We performed comparative studies in spontaneously hy-
pertensive rats (SHR) and Dahl salt-sensitive rats (DS)
[2, 22, 23]. The DS rat is a strain that develops hyperten-
sion only when given high dietary salt. Preglomerular
resistance does not increase in DS rats that are fed a
high-salt diet and become hypertensive, whereas in SHR
appropriate autoregulation via an increase in preglomer-
ular resistance prevents glomerular hypertension. We
demonstrated that at similar levels of systemic hyperten-
sion, glomerular hypertension accompanied by glomer-
ular injury developed in DS rats but not in SHR [25]
(Fig. 2).
Substrains of SHR and Brown Norway rats share a
major histocompatibility complex. Thus, transplantation
of a kidney from a Brown Norway rat into a uninephrec-
tomized hypertensive SHR does not result in immuno-
logic rejection. The kidney does, however, suffer severe
hypertensive injury [27]. This demonstrates that the kid-
ney of the Brown Norway rat is inherently more suscepti-
ble to hypertension-induced damage than is the kidney
of SHR. At present, the reasons for this susceptibility
are not known. Fawn-hooded rats are genetically hyper-
tensive and develop glomerular injury. In response to
an increase in perfusion pressure, these rats have an
impaired ability to increase preglomerular resistance.
The deficit is myogenic in origin and is already present
during the prehypertensive stage in these rats [26, 28].
In glomerular hypertension, the endothelium and mes-
angium are the most vulnerable glomerular structures
[22]. Studies by Lee et al suggested that endothelial cell
injury initiates glomerulosclerosis in response to hyper-
tensive glomerular damage and that the process involves
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Fig. 2. Glomerular hemodynamic changes in
hypertension. Spontaneously hypertensive rats
(SHR) have effective preglomerular resist-
ances. Systemic hypertension is not transmit-
ted to the glomeruli and they do not develop
glomerulosclerosis. Dahl salt-sensitive rats (DS)
have ineffective preglomerular resistances. Sys-
temic hypertension is transmitted to the glo-
meruli and they develop glomerulosclerosis.
(Adapted from [25].)
local upregulation of Ang II synthesis that increases ex-
pression of TGF- and matrix proteins [29].
Glomerular hyperfiltration is an early manifestation
of diabetic nephropathy, which is linked to a decrease
in preglomerular resistances [30]. However, only 20% to
30% of patients with insulin-dependent diabetes mellitus
(IDDM) develop nephropathy [30, 31]. It is tempting to
speculate that the genetic susceptibility for renal disease
in IDDM is in part linked to a genetically conditioned
impairment in renal autoregulation, which is aggravated
by the diabetic milieu. Indeed, recent studies have dem-
onstrated that in hypertensive DS rats, but not in either
normotensive DS rats or hypertensive SHR rats, up-regu-
lation of the glucose transporter GLUT-1 is linked to
a concomitant up-regulation of TGF- [32]. Also, an
increased number of GLUT-1 results in increased glu-
cose transport into mesangial cells, even in the presence
of normoglycemia; both mesangial intracellular increase
in glucose as well as TGF- up-regulate the synthesis of
matrix protein, including collagen and fibronectin, which
are harbingers of glomerulosclerosis. These studies
clearly establish a previously unrecognized link between
hemodynamic factors (glomerular hypertension) and
biochemical metabolic factors (glucose) [32]. Further-
more, these studies would explain the sensitivity to hy-
pertensive injury of the diabetic kidney as well as the
beneficial effect of ACE inhibitors and Ang II receptor
blockers, which reduce glomerular pressure and concom-
itantly inhibit the nonhemodynamic effects of Ang II,
including suppression of TGF- [12, 33].
The antagonistic interaction between NO and Ang
II is particularly evident in the kidney. Experimentally,
inhibition of NO synthesis increases the expression and
up-regulates the synthesis of ACE and Ang II [14, 15].
In the glomerulus, a shift in the balance between NO
and Ang II toward the latter can affect mesangial func-
tion and disturb the glomerular microcirculation by caus-
ing a decrease in the glomerular ultrafiltration coeffi-
cient. More important, mesangial cells respond to Ang
II by increasing O2 production [19], which within the
glomerulus further decreases the bioactivity of NO, gen-
erates peroxynitrite, fosters mesangial cell hypertrophy,
and increases mesangial matrix, a harbinger of glomeru-
lar sclerosis [22].
Blood flow to the renal tubules and the renal intersti-
tium is postglomerular; thus obliteration of glomerular
capillaries due to hypertensive injury produces tubulo-
interstitial ischemia [34]. Proteinuria, a manifestation of
glomerular injury, can further aggravate tubulointersti-
tial injury and inflammation [35]. The importance of in-
flammation in amplifying hemodynamically initiated re-
nal injury was clearly shown in studies of hypertensive
mice with complement deficiency. Indeed, those studies
showed that hypertension induced by deoxycorticoster-
one acetate (DOCA) and salt resulted in dramatically
less glomerular and tubulointerstitial disease in mice de-
ficient in the fifth component of the complement system
(C5) compared with similarly hypertensive congenic mice,
in which levels of the fifth component of the complement
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Fig. 3. Role of complement in hypertensive glomerulopathy. Congenic
mice sufficient and deficient in the fifth component of the complement
system (C5) were made hypertensive with deoxycorticosterone acetate
(DOCA), uninephrectomy, and 1% saline in the drinking water. After
16 weeks, the two groups were similarly hypertensive; however, C5
mice developed less renal injury, suggesting that complement activation
participates in hypertensive renal injury (from [36], with permission).
are normal [36] (Fig. 3). Mice deficient in C5 cannot
assemble the membrane attack complex (MAC), which
is necessary for complement-mediated tissue injury. In
humans, immunofluorescence studies of renal biopsy
specimens showed heavy deposition of the MAC in pa-
tients with hypertension and diabetic nephropathy [37].
Further demonstration of the importance of the host
response to injury comes from recent reports suggesting
that patients who have a genetic condition that results in
an impaired inflammatory response to acute infections,
which results in increased morbidity/mortality due to
these infections, are, paradoxically, less prone to develop
atherosclerosis, a disease with a strong inflammatory
component [38].
Hemodynamic forces such as cyclic strain and shear
stress, which are increased in hypertension, increase en-
dothelial NOS mass and activity and increase NO pro-
duction [39, 40]. Thus, in hypertension the “normal adap-
tive” response of the vascular endothelium to the increased
hemodynamic workload is to up-regulate NOS [2, 39,
40]. Therefore failure of the “normal adaptive” response
would foster vascular injury; however, deficiency in ei-
ther the production or the bioactivity of NO becomes
clearly manifested only when the hemodynamic work-
load of hypertension necessitates an increase in NO pro-
duction to reduce vascular tone and prevent maladaptive
growth changes of the muscle and extracellular matrix
of the heart and vessels [9]. Given the growing evidence
for NO in vascular pathophysiology, we extended our
studies in DS rats and SHR to investigate the role of
NO in hypertensive renal disease as well as its relation-
ship with changes occurring in the left ventricle and large
vessels such as the aorta [2, 23, 25].
Compared with the respective normotensive counter-
parts, we found that aortic NOS mass was increased
106% in SHR but was reduced by 73% in DS rats. In
the kidney, NOS mass was increased 89% in SHR and
reduced 49% in DS (Fig. 4). Aortic hypertrophy did not
occur, and LVH increased only 15% in SHR, whereas
in hypertensive DS rats, aortic hypertrophy and LVH
were increased by 36% and 88%, respectively. In fact,
a significant negative correlation existed between NOS
activity and aortic hypertrophy and LVH [2] (Fig. 5).
Our studies agree with research showing that endothe-
lial NOS knockout mice had a larger increase in vessel
wall thickness (due to vascular smooth muscle hyperpla-
sia) in response to hemodynamically mediated vascular
injury than did wild mice [40]. In the aggregate, these
studies support the notion that NO plays an important
protective role in maintaining cardiorenal homeostasis,
particularly by mitigating vascular smooth muscle hyper-
trophy and hyperplasia, preventing interstitial fibrosis,
and reducing leukocyte-mediated inflammation [21, 22].
From the bench to the bedside: Are Dahl
salt-sensitive rats a paradigm of salt-sensitive
hypertension in humans?
Bigazzi et al reported that hypertensive salt-sensitive
patients are more likely to manifest hyperinsulinemia,
hyperlipidemia, and microalbuminuria than are non-salt-
sensitive hypertensive patients [41]. Reaven, Twersky,
and Chang demonstrated that the DS rats manifest a
defect in insulin-stimulated glucose uptake by isolated
adipocytes [42]. These metabolic changes do not vary as
a function of salt intake and thus suggest that in DS
rats, as in salt-sensitive humans, the susceptibility to the
development of endothelial dysfunction and cardiorenal
disease is part of the cluster of abnormalities that predis-
poses to hypertension [43]. Microalbuminuria is a harbin-
ger of diabetic nephropathy in about 30% of patients
with IDDM [44]. However, several studies have estab-
lished that microalbuminuria is a marker of cardiovascu-
lar morbidity in nondiabetic patients with essential hy-
pertension as well as in patients with type 2 diabetes
mellitus [41]. Because microalbuminuria is common in
salt-sensitive hypertensive patients, it might be a useful
predictor of salt sensitivity, renal disease, and LVH in
patients with essential hypertension [43, 45, 46]. Indeed,
studies in the United States, Europe, and Japan have
confirmed that the incidence of LVH and cardiovascular
events is higher in salt-sensitive hypertensive patients
[42, 46, 47].
Several studies have shown that NO-mediated, endo-
thelium-dependent relaxation contributes to the main-
tenance of vascular compliance. In the aorta, impaired
vascular compliance contributes to the development of
LVH because it increases the impedance to left-ventric-
ular function [48]. In some African American patients,
impaired vascular relaxation mediated by NO precedes
hypertension [49]. It is interesting to speculate that these
Nephrology Forum: Hypertensive renal damage1928
Fig. 4. Link between nitric oxide (NO) and
end-organ injury in hypertension. Nitric oxide
synthase (NOS) in aortas and kidneys from
normotensive Dahl salt-sensitive rats (DS)
and Wistar-Kyoto (WKY) rats and hyperten-
sive DS and spontaneously hypertensive rats
(SHR). Systolic blood pressure (SBP): DS-
0.5% 133  3 mm Hg; DS-4.0% 220  8
mm Hg; WKY 137  3 mm Hg; and SHR
220 9 mm Hg. *P 0.5 vs. DS-0.5%; **P
0.5 vs. WKY. Values are mean  SE. DS rats
were from the Brookhaven strain (from [9],
with permission).
Fig. 5. Link between nitric oxide (NO) and end-organ injury in hypertension. Urinary protein excretion (UproV), glomerular injury score (GIS),
left ventricular hypertrophy (LVH), and aortic hypertrophy score in hypertensive Dahl salt-sensitive (DS-4%) (systolic blood pressure 220  8
mm Hg), and spontaneously hypertensive rats (SHR) 220  9 mm Hg. Values are mean  SE. DS rats were from the Brookhaven strain (from
[9], with permission).
patients might become salt sensitive over time. Further,
aging per se is accompanied by an increased prevalence
of hypertension, salt sensitivity, and decreased endothe-
lium-dependent relaxation mediated by NO [50].
Are there populations of humans with characteristics
similar to those of SHR?
Patient 2 is an example of patients with a form of auto-
somal-dominant hypertension characterized by brachy-
dactyly and severe hypertension who have minimal
LVH, no renal injury, normal endothelial function, ab-
sence of retinopathy, and no salt sensitivity [1]. Similar
families have been described in the United States and
Canada.
In summary, comparisons of experimental and epide-
miologic studies clearly indicate that in hypertension
end-organ injury affects all organs, although the severity
of end-organ injury varies considerably. At the same time,
the prevalence of the major causes of morbidity and
mortality in hypertension—namely, LVH, renal failure,
and CAD—varies in different populations of hyperten-
sive patients and suggests that susceptibility to cardiovas-
cular and renal disease is not uniform.
In hypertension, an increase in the pressure workload
fosters adaptive changes in the endothelium, the vascular
smooth muscle, the extracellular matrix of vessels, the
kidney, and the heart. In many patients, the end-organs’
adaptive changes to hypertension are, in fact, maladap-
tive. Environmental and metabolic factors conspire to
induce an imbalance between NO and Ang II, and this
imbalance appears to play a pivotal role in conditioning
individual susceptibility for the development and pro-
gression of end-organ failure from hypertension.
QUESTIONS AND ANSWERS
Dr. Nicolaos E. Madias (Dean ad interim, Tufts Uni-
versity School of Medicine, Boston, Massachusetts): Over-
activity of the Na/H antiporter (NHE-1 isoform) has
been identified in a variety of cell types of patients with
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type 1 diabetes and nephropathy as compared to those
without nephropathy [31]. Also, an overactive NHE-1
isoform has been found in immortalized lymphocytes
of hypertensive subjects [51]. Is it known whether such
overactivity in hypertension is confined to patients with
associated renal injury?
Dr. Raij: I am not aware of a study that has addressed
this issue.
Dr. Oliver Lenz (Staff Physician, Nephrology-Hyper-
tension Division, Vascular Biology Institute, University
of Miami School of Medicine, Miami, Florida): Multiple
lines of evidence suggest that the risk for a given individ-
ual to develop glomerulosclerosis and the rate of progres-
sion are largely under genetic control [52–55]. Several
studies have been undertaken to identify quantitative
trait loci and candidate genes associated with the risk of
developing renal disease, most notably in the course of
diabetes and hypertension [53, 55, 56]. In patients with
hypertension, a polymorphism in the angiotensinogen
gene has been associated with hypertension, and an in-
sertion/deletion polymorphism in the ACE gene might
be associated with renal disease [57, 58]. However, the
clinical relevance of these data is controversial [59]. Do
you think the genome holds the key to the prevention
of end-stage renal disease in hypertension?
Dr. Raij: I do believe that the genome holds one of
the keys to the prevention of end-stage renal disease
and hypertension. However, it would be naı¨ve of us to
think that environmental and social conditions do not
participate in the modification of genetic influences.
Dr. Murray Epstein (Nephrology Division, University
of Miami School of Medicine): In addition to variations
in Ang II and NO, could differences in aldosterone deter-
mine an individual’s susceptibility for developing end-
organ disease? We recently reported that selective aldo-
sterone blockade with eplerenone reduces proteinuria
in diabetic hypertensive patients [60]. Furthermore, this
effect is additive to ACE inhibition. Consequently, dif-
ferences in aldosterone levels or aldosterone respon-
siveness might influence susceptibility to target organ
disease [60].
Dr. Raij: I find that comment very interesting, particu-
larly because most studies either in patients with diabetic
nephropathy or in hypertensive patients with chronic
renal failure have shown that inhibition or blockade of
the renin-angiotensin system reduces the risk of progres-
sion by approximately 30%. This suggests that there is
enough room for other agents such as aldosterone block-
ers to have additive or synergistic effects.
Dr. Edgar A. Jaimes (Nephrology Section, VA Medi-
cal Center, and Nephrology-Hypertension Division, Uni-
versity of Miami School of Medicine): I would like to
add that aldosterone has significant inflammatory effects
in different tissues including the kidneys, and these ac-
tions seem to be independent from those of Ang II
[61, 62].
Dr. Raij: Yes, I am aware of those studies, and I find
them very exciting. Furthermore, the studies by Karl
Weber and his group also strongly suggest that aldoste-
rone has an important fibrotic effect [63]. I wonder
whether these effects are also important in the kidney.
Dr. Barry J. Materson (Medical Director for Man-
aged Care, University of Miami School of Medicine):
Given the growing body of clinical and experimental
evidence regarding the combination of ACE inhibitors
or AT1 receptor blockers with spironolactone or eplere-
none, is there any evidence in vitro that any two of these
drugs or all three together increase the up-regulation of
nitric oxide synthase? I should note that this presumes
that ACE inhibitors as well as ARBs “de-repress” NOS
by either reducing Ang II generation or blocking its
receptors. It also presumes that mineralocorticoid recep-
tor blockers have anything to do with the issue.
Dr. Raij: Experimentally and clinically, normalization
of blood pressure as well as specific actions of ACE
inhibitors and AT1 receptor blockers improve NO bio-
activity via multiple pathways that I discussed. Whether
blockade of aldosterone will also increase NO indepen-
dently of its effect on blood pressure is unknown. My
laboratory is currently engaged in those studies.
Dr. Debasish Banerjee (Renal Fellow, Nephrology
Hypertension Division, University of Miami School of
Medicine): My question is in the context of the elevation
of nocturnal systolic blood pressure as an early marker
of one’s increased susceptibility for developing micro-
albuminuria in type 1 diabetes. In that study, the sys-
tolic–in contrast to the diastolic–blood pressure elevation
at night was associated with renal injury [64]. Can early
changes in systolic blood pressure be used as a clinical
marker to identify the high-risk patient?
Dr. Raij: I am not aware of any studies, other than
the one that you quoted [64], that have suggested that
mild systolic hypertension initiates progressive glomeru-
lar injury. My speculation would be that in patients with
abnormal autoregulation of preglomerular resistances,
either continuous or intermittent elevations in systolic
blood pressure initiate glomerular injury and progressive
renal failure. In this context, I find the studies by Gnudi
et al [32] and Lurbe et al [64] quite exciting. On the other
hand, there is no question that systolic hypertension is
an important risk factor in the progression of renal fail-
ure. In fact, systolic hypertension imposes a similar in-
crease in risk for the development of cerebrovascular
accident and renal disease.
Dr. Madias: You mentioned that you can identify
endothelial dysfunction in certain people prior to clinical
disease. Have any studies looked into whether defective
renal autoregulation accompanies this endothelial dys-
function?
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Dr. Raij: No, although these studies need to be done.
Dr. Richard A. Preston (Chief, Division of Clinical
Pharmacology, University of Miami School of Medicine):
We determined sVCAM, sICAM, and von Willebrand
factor (vWF) levels in severe hypertensives (SHT), mild
hypertensives (MHT), and normotensive (NT) volunteer
subjects and found all three markers to be greater in
SHT and MHT than in NT, but they did not differ be-
tween SHT and MHT. Further, we found no correlation
between the markers and blood pressure. Concentra-
tions of soluble adhesion molecules and vWF might de-
pend more strongly on factors in the hypertensive micro-
environment other than the absolute level of blood
pressure per se. This suggests that mechanisms other
than the endothelial expression of adhesion molecules
are important in mediating the accelerated target organ
injury observed in severe hypertension in humans and
that the response of endothelial markers to blood pres-
sure varies significantly in the severely hypertensive pop-
ulation [65, 66].
Dr. Raij: Your studies are potentially very important.
In the context of the two cases that I presented, the
up-regulation of inflammatory and fibrogenic molecules
might have greater injurious potential in patients similar
to the first patient than the second. Indeed, it will be
fascinating to explore this possibility by studying hyper-
tensive individuals with high susceptibility to end-organ
injury and those fairly resistant, such as patients similar
to Patient 2. On the other hand, blood levels of these
molecules might not quite express what is going on in
the “hypertensive microenvironment” as you suggest.
Dr. Baudouin Leclercq (Staff Physician, Nephrol-
ogy-Hypertension Division and Vascular Biology Insti-
tute, University of Miami School of Medicine): During
your presentation, you showed that in rats, end-organ
damage was induced, at least partially, by sodium chlo-
ride. Is information available about the influence of salt
intake or salt sensitivity on the interaction between Ang
II and NO?
Dr. Raij: It’s difficult to extrapolate animal data to
humans. But I can tell you that in vitro and in vivo studies
have shown that salt can up-regulate AT1 receptors. Our
rats manifest an up-regulation of AT1 receptors; at least,
there’s a “functional up-regulation” of AT1 receptor-
mediated activity in our salt-sensitive rats. But I do not
know how that is mediated at a molecular level.
Dr. Madias: Some data have implicated the number
of nephrons that humans or experimental animals are
born with–as a consequence of malnutrition or other
circumstances–as a factor predisposing to renal injury in
a hypertensive subject. Can you tell us about that?
Dr. Raij: As you pointed out, the data suggest that
DS rats have fewer nephrons than do SHR rats. The
natural adaptation to a reduction in renal mass is an
increase in the glomerular filtration rate/nephron that is
mediated by dilating pre-glomerular arterioles. Rats with
reduced renal mass (for example, the remnant kidney
model) develop hypertension, have impaired glomerular
autoregulation of flows and pressures, and sustain glo-
merular injury. Indeed, induction of the classic remnant
kidney in rats that up-regulate NOS in response to this
maneuver does not result in hypertension or glomeru-
lar injury (abstract; Erdely A et al, J Am Soc Nephrol
11:617A, 2000).
Dr. David Roth (Chief, Nephrology and Hypertension
Division, University of Miami School of Medicine): We
know that in renal transplantation in humans, a cadaver
kidney from an African American donor transplanted
into a white recipient has about a 25% to 30% increased
risk of graft failure compared to an organ from a white
donor. These are kidneys harvested from individuals
with no known history of hypertension or renal disease.
In the context of the article by Churchill and colleagues,
in which a kidney from a Brown Norway rat transplanted
into an SHR is far more susceptible to hypertensive
injury [27], and knowing as we do that the incidence of
renal disease in African Americans is several times that
of the white population, do you think that genetic charac-
teristics or other factors accompany the kidney into the
recipient and that these explain the higher incidence of
graft failure in this setting?
As a follow-up, are you aware of any studies that
examined the family history of the organ donor and
correlated a strong donor family history of hypertension
with outcome in the recipient?
Dr. Raij: Those are two fascinating questions, both
of which are testable. I would hope that we could develop
clinical studies that will be able to answer those ques-
tions.
Dr. Carlos Abraira (Endocrinology Division, Uni-
versity of Miami School of Medicine): The hypothesis of
a differential regulation of intraglomerular pressure in
the presence of arterial hypertension, and its potential
critical role on the development or progression of dia-
betic nephropathy, is very attractive and testable. A frac-
tion of type 2 diabetic patients are vulnerable to renal
insufficiency due to diabetes [67]. At least one-half of
type 1 diabetic patients will never develop it regardless
of duration [67].
On the other hand, given enough time, virtually all
diabetic patients develop retinopathy [68]. Nonetheless,
blood pressure control is very effective in preventing or
delaying the appearance or progression of lesions in the
retina [69]. Does intravascular pressure regulatory dys-
function play a role in the susceptibility of the eye to
hypertensive damage in diabetes?
Dr. Raij: My expertise in the area of autoregulation
in blood flow in the retina is very limited. However, I
am familiar with some studies that have reported that
ACE inhibitors might be more effective than other
Nephrology Forum: Hypertensive renal damage 1931
agents in arresting the progression of retinopathy in dia-
betics [69]. I know that you are conducting an important
multicenter study looking at risk factors in type 2 diabet-
ics. You might be able to elucidate some aspects of your
question when you analyze your data at the completion
of the study.
Reprint requests to Dr. Leopoldo Raij, Nephrology-Hypertension
Division, Veterans Affairs Medical Center, 1201 NW 16th Street, Room
A-1009, Miami, Florida 33125.
E-mail: Lraij@med.miami.edu
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